Welcome to our dedicated page for Abbvie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for AbbVie Inc. (NYSE: ABBV), a pharmaceutical preparation manufacturing company focused on immunology, oncology, neuroscience, eye care and its Allergan Aesthetics portfolio. AbbVie’s filings provide structured insight into its financial condition, capital structure, research spending and key corporate events.
Recent Form 8‑K filings discuss items under “Results of Operations and Financial Condition,” including guidance for specific quarters and full‑year periods and the impact of acquired in‑process research and development (IPR&D) and milestones expense on diluted earnings per share. Other 8‑K disclosures describe settlements of litigation related to generic manufacturers of upadacitinib tablets (marketed as RINVOQ) and note that AbbVie’s common stock and multiple series of senior notes are registered and listed on the New York Stock Exchange.
Through this filings feed, users can access AbbVie’s current reports alongside its periodic reports when available, such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q. These documents typically contain details on research and development activities, manufacturing investments, and the performance of key therapeutic areas, as well as discussions of risk factors and capital allocation. For a company active in oncology and other complex therapeutic fields, these filings help explain how collaborations, licensing agreements and acquisitions are reflected in financial statements, particularly through acquired IPR&D and milestones expense.
Stock Titan enhances these filings with AI-powered summaries that highlight important sections, such as earnings guidance updates, litigation disclosures and changes in capital structure. Users can quickly see how items like AbbVie’s guidance revisions, settlement agreements or investment commitments appear in official SEC documents. Real-time updates from EDGAR, combined with AI explanations of forms such as 8‑K and, where applicable, 10‑K, 10‑Q and Form 4 insider transaction reports, allow investors and researchers to review ABBV’s regulatory record more efficiently and understand the context behind headline numbers and corporate announcements.
AbbVie Inc. updated its 2026 earnings guidance to reflect a sizeable first-quarter charge for acquired in-process R&D and milestones. The company expects to record $744 million of pre-tax acquired IPR&D and milestones expense in the first quarter of 2026, which is estimated to reduce both GAAP and adjusted diluted earnings per share by $0.41.
Including this impact, AbbVie now guides full-year 2026 adjusted diluted EPS to a range of $13.96 to $14.16, compared with prior guidance that excluded this expense. First-quarter 2026 adjusted diluted EPS guidance, including the charge, is $2.56 to $2.60, down from the previously announced range of $2.97 to $3.01 that did not include the IPR&D and milestones expense.
Quaggin Susan E reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Susan E. Quaggin reported a compensation-related award of 71 stock equivalent units tied to AbbVie common stock at a reference value of $217.49 per unit. Following this grant, her balance in these units increased to 784 stock equivalent units.
The units represent director fees credited to a stock equivalent unit account under a grantor trust established by the director and are generally paid in cash at around age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock, and the balance also reflects units accumulated through a dividend reinvestment feature.
RAPP EDWARD J reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Edward J. Rapp received a grant of 155 Stock Equivalent Units on March 31, 2026. The units were credited as director fees at a reference price of $217.49 per unit and are linked to AbbVie common stock performance.
Following this grant, Rapp holds a reported total of 28,865 Stock Equivalent Units. These units are maintained in a grantor trust established by the director and are generally paid in cash at age 65 or upon retirement from the board, with value tracking AbbVie stock, including a dividend reinvestment feature.
Alpern Robert J reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Robert J. Alpern received a grant of 35 stock equivalent units tied to AbbVie common stock as director compensation. The units were credited on the basis of director fees at a reference value of $217.49 per unit and track the return of AbbVie shares.
Following this award, Alpern’s balance increased to 10,369 stock equivalent units held in grantor trust accounts. These units are payable in cash, generally at age 65 or when he retires from the AbbVie board, and the balance also reflects units added through a dividend reinvestment feature.
The Vanguard Group filed Amendment No. 12 to a Schedule 13G/A reporting 0% ownership of AbbVie Inc. The filing states an 0 amount of common shares beneficially owned and shows 0% of the class. The filing explains an internal realignment completed January 12, 2026 that caused certain Vanguard subsidiaries/divisions to report separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
AbbVie Inc. has released its 2026 proxy statement for the May 8, 2026 virtual annual meeting, asking stockholders to elect four Class II directors, ratify Ernst & Young as auditor, approve executive pay on an advisory basis, and back a management proposal to eliminate supermajority voting. The board recommends voting against a stockholder proposal seeking an independent board chair.
The proxy highlights 2025 total net revenues of $61.2BN, growth platform net revenues of $56.6BN, and operating cash flow of $19.0BN, along with 12 blockbuster products and about 90 active clinical and device programs. Over the last decade, AbbVie reports a market capitalization increase of $309BN, quarterly dividend growth from $0.57 to $1.73 per share, and total stockholder return of +485%, outpacing the S&P 500 and NYSE Arca Pharmaceutical Index.
The board emphasizes strong governance and ESG practices, including a majority-independent board with a lead independent director, clawback, anti-hedging and anti-pledging policies, and proxy access. Executive pay is described as heavily performance-based, with more than three-fourths of named executive officer compensation tied to non-GAAP financial, strategic, and long-term equity incentives aligned with stockholder returns.
AbbVie Inc. senior vice president and controller David Ryan Purdue reported a routine tax-related share disposition. On February 27, 2026, 2,108 shares of AbbVie common stock were withheld at $232.08 per share to cover tax obligations, a non-market transaction coded as a tax-withholding disposition.
After this event, Purdue directly held 8,468 shares of AbbVie common stock. He also had an additional 543 shares held indirectly through a profit sharing trust tied to an AbbVie savings program, with that balance stated as of February 20, 2026 and including shares from dividend reinvestment.
AbbVie Inc. is soliciting votes for its 2026 Annual Meeting of Stockholders to be held virtually on May 8, 2026 for holders of record as of March 9, 2026. The proxy lists five voting items: election of directors; ratification of Ernst & Young LLP as independent auditor; an advisory "say on pay" for executive compensation; a management proposal to eliminate supermajority voting thresholds; and a stockholder proposal requesting an independent board chair. The proxy highlights 2025 operational and financial metrics, including $61.2BN total net revenues, $56.6BN growth platform net revenues, $19.0BN operating cash flow, $13.8BN adjusted R&D investment, and a +8.5% operational growth figure. It also cites long-term shareholder returns: +485% total stockholder return over 10 years and a +$309BN increase in market capitalization (as of 12/31/2025). The proxy describes board composition, recent leadership changes including Mr. Robert A. Michael serving as CEO and Chair, governance practices, ESG oversight and disclosures, director nominee biographies, director compensation, securities ownership tables, and the Compensation Discussion and Analysis for named executive officers.
AbbVie Inc. senior vice president and controller David Ryan Purdue sold 5,230 shares of AbbVie common stock in an open-market transaction at $233.56 per share on March 4, 2026. After the sale, he directly held 2,654 shares.
A separate entry shows 543 AbbVie shares held directly in an AbbVie Savings program as of February 20, 2026, with that balance including shares acquired through a dividend reinvestment feature.